Sight Sciences, Inc. (SGHT)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Sight Sciences (SGHT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sight Sciences: Improving Medicare Coverage Drives Eye-Popping Price Surge
Sight Sciences surged over 100% after two major Medicare contractors approved coverage for its TearCare dry eye treatment. Positive reimbursement decisions for TearCare open up a sizable market opportunity ($400 ASP and multiple millions of treatable patients) that was severely limited on a self-pay basis. OMNI is still the much larger business today, and while the company secured a positive reimbursement decision, market penetration may be limited or slowed by the company's tight finances.
What Makes Sight Sciences, Inc. (SGHT) a Strong Momentum Stock: Buy Now?
Does Sight Sciences, Inc. (SGHT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Sight Sciences (SGHT) Upgraded to Buy: Here's What You Should Know
Sight Sciences (SGHT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Sight Sciences, Inc. (SGHT) Q3 2025 Earnings Call Transcript
Sight Sciences, Inc. ( SGHT ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Paul Badawi - Co-Founder, President, CEO & Director Jim Rodberg - VP of Finance & Corporate Controller Alison Bauerlein - CFO, Principal Financial & Accounting Officer and Treasurer Conference Call Participants Hannah Jeffrey - The Gilmartin Group Danielle Antalffy - UBS Investment Bank, Research Division David Saxon - Needham & Company, LLC, Research Division Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division Adam Maeder - Piper Sandler & Co., Research Division Xuesong Wang - Morgan Stanley, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to Sight Sciences Third Quarter 2025 Earnings Results Conference Call.
Sight Sciences (SGHT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Tops Revenue Estimates
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.22 per share a year ago.
Sight Sciences, Inc. (SGHT) Q2 2025 Earnings Call Transcript
Sight Sciences, Inc. (NASDAQ:SGHT ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Alison Perry Bauerlein - CFO, Principal Financial & Accounting Officer and Treasurer Matthew W. Link - Chief Commercial Officer Paul Badawi - Co-Founder, President, CEO & Director Conference Call Participants Danielle Joy Antalffy - UBS Investment Bank, Research Division Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division Joanne Karen Wuensch - Citigroup Inc. Exchange Research Kyle Edward Winborne - Piper Sandler & Co., Research Division Thomas M.
Compared to Estimates, Sight Sciences (SGHT) Q2 Earnings: A Look at Key Metrics
The headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.25 per share a year ago.
Sight Sciences, Inc. (SGHT) Q1 2025 Earnings Call Transcript
Sight Sciences, Inc. (NASDAQ:SGHT ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Hannah Jefferies - Investor Relations Paul Badawi - Co-Founder & CEO Ali Bauerlein - CFO Matt Link - Chief Commercial Officer Conference Call Participants Tom Stephan - Stifel Danielle Antalffy - UBS Joanne Welsh - Citi Frank Takkinen - Lake Street Capital Markets Macauley Kilbane - William Blair David Saxon - Needham & Company Operator Good day, and thank you for standing by. Welcome to the Sight Sciences First Quarter 2025 Earnings Results Conference Call.
Sight Sciences (SGHT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Sight Sciences (SGHT) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
